Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + carboplatin + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
The drug combination "albumin-bound paclitaxel + carboplatin + toripalimab" is a therapeutic regimen combining three medications for cancer treatment, primarily non-small cell lung cancer (NSCLC). Albumin-bound paclitaxel (also known as nab-paclitaxel or Abraxane) is a solvent-free formulation of paclitaxel using albumin for delivery. It allows for less premedication, shorter infusion time, higher doses, and potentially better tumor penetration. Carboplatin is a platinum-based chemotherapy drug that interferes with DNA replication. Toripalimab is a monoclonal antibody and PD-1 immune checkpoint inhibitor. This combination therapy works by leveraging multiple mechanisms: albumin-bound paclitaxel disrupts microtubule function, carboplatin damages DNA, and toripalimab enhances the immune system's ability to target cancer cells. The combination of albumin-bound paclitaxel with carboplatin is an approved first-line treatment for unresectable NSCLC. The addition of toripalimab adds an immunotherapy component aimed at enhancing efficacy.
- Brand names
- LoqtorziAbraxane
- Other names
- toripalimab plus platinum-based doubletnab-paclitaxel + carboplatin + toripalimabalbumin-bound paclitaxel + carboplatin + toripalimab-Hao Long-non-small cell lung cancer
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)MicrotubuleDNA
Beyond the preview
Go deeper on albumin-bound paclitaxel + carboplatin + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + carboplatin + toripalimab.